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Abstract
 
 
Objectives: The aim of this study was to compare 
standard triple therapy regimen with sequential ther-
apy regimen containing levofloxacin used for the 
eradication of H. pylori in patients with gastrointesti-
nal infection caused by H. pylori.
Methods: This single blind clinical trial study was 
conducted on 96 patients with positive Rapid Ure-
ase Test (RUT) who were referred to the Endoscopy 
center of Hajar Hospital in Shahrekord city, located 
in southwest of Iran. The patients were randomly as-
signed into two treatment groups: sequential therapy 
regimen and triple therapy regimen. The patients in 
the first group received sequential therapy regimen 
including omeprazole, amoxicillin, levofloxacin, and 
tinidazole; the second group of patients received 
a triple therapy regimen consisting of omeprazole, 
amoxicillin, and clarithromycin. Four weeks after the 
end of the treatment, using H. pylori Stool Antigen 
(HpSA), a test was performed to prove the eradica-
tion of H. pylori. The influences of patients’ age, gen-
der and eradication level were also investigated.
Results: There were significant differences between 
the two groups in terms of age and education. While 
H. pylori eradication rate was 67.3% in the sequen-
tial therapy regimen, it was 66% in standard triple 
therapy regimen. In addition, among patients receiv-
ing triple therapy regimen, being aged older than 40 
years had a significant relationship with eradication. 
Moreover, in patients receiving sequential therapy 
regimen, education level had a significant relation-
ship with eradication.
Conclusion: There was no statistically significant dif-
ference between the two therapy groups in terms 
of H. pylori eradication rate. However, given the 
low rates of H. pylori eradication in both sequential 
and triple therapy regimens observed in the present 
study, it seems that it is necessary to conduct fur-
ther research on the bacterial resistance to the pre-
scribed antibiotics. 
Key words: H. pylori, standard triple therapy, 
sequential therapy, Eradication
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Introduction
H. pylori is a microaerophilic gram-negative bacterium 
which has affected more than half of the world population 
[1-6]. Infections caused by H. pylori are known as the 
main cause of chronic gastritis disease type B, peptic 
ulcer, and mucosa associated lymphoid tissue (MALT) 
lymphoma; in addition, the treatment of related infections 
are recommended to prevent adenocarcinoma gastric 
cancers [7-14]. The guidelines proposed for the treatment 
of H. pylori infection have emphasized on the eradication 
of the bacteria using multiple medication regimens [15]. 
Nevertheless, treatment success rate depends on several 
factors including type of antibiotic, dosage, formulation, 
duration of treatment, patient compliance, smoking, 
and bacterial resistance to one or more antibiotics [16]. 
Resistance to antibiotics is the most common cause of 
failure in achieving an eradication rate of higher than 80% 
[12, 17, and 18]. Moreover, using the same regimens, the 
rates of relapse and re-infection in developing countries 
are higher than those in other countries [19]. 
According to studies conducted in Iran, the prevalence of 
H. pylori resistance to clarithromycin, furazolidone, and 
metronidazole is remarkably increasing and the level of 
resistance to amoxicillin is much higher than that in other 
countries [20, 21]. Hence, as the result of the increase 
in bacterial resistance to common antibiotic regimes and 
differences in resistance patterns in different regions, 
there have been some differences in therapy regimens 
and techniques used in different areas [22-24]. Quadruple 
therapy is a conventional therapy regimen which consists 
of a proton pump inhibitor drug, amoxicillin, metronidazole, 
and clarithromycin [15,25-27]. Resistance to clarithromycin 
and metronidazole has increased in recent years. 
Resistance to metronidazole has also been observed in 40-
50% of people in developed countries and 80% of people 
in developing countries [12]. In Iran, the prevalence of 
resistance to clarithromycin and metronidazole are about 
16.7% and 57.5%, respectively [21]. 
Sequential therapy is one of the methods which have had 
promising outcomes in recent years. Using sequential 
therapy, an eradication rate of more than 80% has been 
achieved and patients have tolerated it well [12]. Vaira and 
colleagues compared two regimens of triple therapy and 
sequential therapy for 10 days; According to their findings, 
using triple therapy and sequential therapy regimens, 
eradication rates of 77% and 89%, respectively, were 
achieved. It shows that sequential therapy had resulted in 
higher eradication rate, in comparison with the standard 
triple therapy [28]. In Polat ’s study, H. pylori eradication 
rate was significantly higher in the group undergoing 
sequential therapy, compared to the group undergoing 
triple therapy [29].
To avoid treatment failure and the development of 
secondary resistance to antibiotics, it is necessary to 
select an appropriate treatment regimen as the first line 
treatment; hence, it is of great value to conduct research 
to evaluate the effectiveness of common therapy regimens 
for the eradication of the bacteria, compare these methods 
and finally identify the most effective and the safest 
treatment regimen. Moreover, Levofloxacin is a medication 
that is commonly used in such therapy regimens and it 
has been introduced into the pharmacopoeia of Iran in 
recent years. Therefore, to identify an effective treatment 
regimen to reduce antibiotic resistance and to achieve 
bacteria eradication, this study aimed to compare standard 
triple therapy regimen with sequential therapy regimen 
containing levofloxacin used for the eradication of H. 
pylori in patients with gastrointestinal infection caused by 
H. pylori.
Materials and Methods
Study population
This single blind clinical trial was conducted on 96 patients 
with dyspepsia and positive Rapid Urease Test (RUT) who 
were referred to the endoscopy center of Hajar Hospital 
in Shahrekord city, located in southwest of Iran, from May 
to August 2015. This study was approved by the Ethics 
Committee of Shahrekord University of Medical Sciences, 
Shahrekord, Iran. Eligible patients were selected in the 
study period. Patients with drug resistance and drug 
intolerance or other complications and those unwilling 
to continue the study were excluded. To determine the 
sample size, we considered the quantitative changing 
condition of the sample size and took into account the 
Type I error (α) of 0.05 and Type II error (β) of 0.20 (power 
of 80%); accordingly, the sample size was determined as 
50 patients per group.
The patients with dyspepsia and positive RUT who were 
referred for outpatient services and admitted to endoscopy 
center were randomly assigned to one of the two groups. 
To maximize the randomization process and assign 
patients to the groups, the necessary medications for each 
group were taken out of their packages and were placed 
in opaque envelopes whose content was not visible. The 
envelopes were titled by the letters A and B; each letter 
represented a particular treatment group. Patients were 
not aware of the type of treatment group. Each patient 
received a piece of paper on which type of therapy 
regimen was determined by the letters A (triple therapy 
regimen) or B (sequential therapy regimen containing 
levofloxacin). All the patients were trained about how to 
take the drugs; then, the patients were asked to visit their 
physician whenever they experienced any problems during 
treatment, especially when facing drug complications or 
being forced to discontinue the treatment.
After assigning the patients to the groups, the patients 
in Group A who were under triple therapy for 10 days, 
received omeprazole 20 mg twice a day, amoxicillin 1 g 
twice a day, and clarithromycin 500 mg twice a day. The 
patients in group B, who were under sequential therapy 
regimen, for five days received omeprazole 20 mg twice a 
day and amoxicillin 1 g twice a day; in the next five days, 
they received levofloxacin 250 mg twice a day, omeprazole 
20 mg twice a day, and tinidazole 500 mg twice a day. Four 
weeks after the end of the therapy regimen, the patients 
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were visited by a doctor and using H. pylori Stool Antigen 
(HpSA), a test was performed to prove the eradication of H. 
pylori. The patients were informed about the time of HpSA 
test in advance and they were warned not to take proton-
pump inhibitors (25-27), antibiotics, and bismuth before 
the test. If the patients were forced to take any medication 
within two weeks before the test, the patient would have 
been asked to notify the research team to schedule a new 
date for performing HpSA test.
Ethical issues
1) The research followed the tenets of the Declaration 
of Helsinki; 2) informed consent was obtained, and 3) 
the research was approved by the ethical committee 
of Shahrekrod University of Medical Sciences (Ethical 
code#IR.SKUMS.REC.1394.71).
Statistical analysis
Data collection was conducted through using a questionnaire 
which collected demographic data including age, sex, and 
education level and recorded the results of HpSA test. 
Analysis of the data was performed using SPSS version 
18. Continuous quantitative variables were analyzed using 
T test and qualitative variables were analyzed using chi-
square test.
Results
Of all the patients, three patients in group A and one patient 
in group B were excluded from the study; as a result, the 
remaining 96 patients were randomly assigned to the 
two groups receiving sequential therapy regimen with 
levofloxacin (49 patients) and triple therapy regimen (47 
patients). The mean age of the patients in the sequential 
therapy group and triple therapy group was 33.29 ± 1.54 
years and 45.53 ± 2.17 years, respectively. There was a 
significant difference between the two treatment groups in 
terms of the mean age (p = 0.00). However, there was no 
significant difference between the two treatment groups 
in terms of patients’ sex distribution (p = 0.57). Moreover, 
there was also a significant difference between the two 
treatment groups in terms of the distribution of patients in 
different education groups (p = 0.00). Table 1 presents the 
data on patients’ age, sex, and education level.
Of the patients in the two groups, 67.3% of the patients 
in the sequential therapy group and 66% of the patients 
in the triple therapy group had negative HpSA (H. pylori 
Stool Antigen); there was no significant difference between 
the two treatment groups in terms of the eradication of 
H. pylori (p = 0.99) (Table 2). In addition, concerning the 
side effects of the medications, one person (2%) in the 
sequential therapy group (because of the nausea caused 
Table 1: Demographic data of patients in the two treatment groups receiving triple therapy regimen and 
sequential therapy regimen to eradicate H. pylori
* P < 0.05 is considered as significant.
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Table 2: Comparison of the results of stool antigen test between the two treatment groups receiving triple 
therapy regimen and sequential therapy regimen to eradicate H. pylori
  
* p < 0.05  is considered as significant.
 
Table 3: Comparison of the effects of patients’ age on the efficacy of treatment (based on the results of stool 
antigen test) between the two groups receiving triple therapy regimen and sequential therapy regimen to 
eradicate H. pylori
 
* p < 0.05  is considered as significant.
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by amoxicillin) and one person (2.1%) in the triple therapy 
group (because of the cramps caused by clarithromycin) 
were unable to tolerate the drug. However, the rest of 
the participants in this study did not report any treatment-
specific complaints.
The results of stool antigen test were used to assess 
the effects of patients’ age on the efficacy of sequential 
therapy and triple therapy for the eradication of H. pylori. 
The results showed that when comparing the patients 
aged 40 years and younger between the two treatment 
groups, there was no significant difference between them 
in terms of the treatment outcome (p = 0.32); however, 
when comparing patients aged over 40 years, there was a 
significant difference between the two treatment groups in 
terms of response to treatment. Accordingly, the response 
to treatment was better in the triple therapy group (p = 
0.045) (Table 3).
The effects of education levels on eradication of H. pylori 
were assessed; according to the results, the responses to 
the treatment in sequential therapy group were significantly 
different between different education groups (p = 0.01), 
but in the triple therapy group there was no significant 
difference between different education groups in terms of 
the response to treatment (p = 0.46) (Table 4). There was 
a significant difference between the two groups of patients 
with education levels lower than high-school diploma and 
academic education in terms of response to treatment (p 
= 0.048). There was also a slightly significant difference 
between the two groups of patients with high-school 
diploma and academic education in terms of response to 
treatment (p = 0.063). However, there was no significant 
difference between the two groups of patients with an 
education level lower than high school diploma and with 
high school diploma in terms of response to treatment (p 
= 0.89).
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Table 4: Comparison of the effects of patients’ education on the efficacy of treatment (based on the results of 
stool antigen test) between the two groups receiving triple therapy regimen and sequential therapy regimen to 
eradicate H. pylori
* p < 0.05  is considered as significant
Table 5: Comparison of the effects of patients’ sex on the efficacy of treatment (based on the results of stool 
antigen test) between the two groups receiving triple therapy regimen and sequential therapy regimen to 
eradicate H. pylori
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The effect of sex on eradication of H. pylori was also 
assessed. In the triple therapy group, there was no 
significant difference between females and males in 
terms of response to treatment (p = 0.64); however, in 
the sequential therapy group, a significant difference 
was observed between females and males in terms 
of response to treatment (p = 0.009). Accordingly, the 
response to treatment was better in males than females in 
the sequential therapy group (Table 5).
Discussion
This study was conducted to compare standard triple 
therapy regimen with sequential therapy regimen containing 
levofloxacin used for the eradication of H. pylori in patients 
with gastrointestinal infection caused by H. pylori. H. pylori 
eradication rate was 67.3% in the sequential therapy 
regimen and 66% in standard triple therapy regimen. As 
the main goal of treatment is to eradicate the infection in 
85-95% of the patients; however, because of the lower 
treatment success rates observed in this research, hence, 
these two regimens in this study is not recommended. 
Several studies have been conducted on standard triple 
therapy in Iran. In a study by Aminian and colleagues, 
the regimen consisted of omeprazole 20 mg twice a day, 
amoxicillin 1 g twice a day, and clarithromycin 500 mg twice 
a day which had been administered for 10 days with the 
eradication rate of 90.7% [30]. Moreover, Keshavarz and 
colleagues used the above-mentioned treatment regimen 
for seven days and reported an eradication rate of about 
87.5% [31]. 
Furthermore, one of the most common causes of treatment 
failures could be the emergence of new antibiotic-resistant 
bacterial strains [32]. In this study, the emergence of H. 
pylori strains resistant to the antibiotics might have been 
a cause of treatment failure. In a similar study conducted 
by Polat and colleagues, of a total of 72 patients receiving 
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sequential regimen containing levofloxacin, 65 patients 
were affected by gram-negative bacteria, while of a total of 
67 patients receiving standard triple therapy regimen, only 
34 patients were affected by gram-negative bacteria [29], 
which may refer to the fact that in different geographic areas, 
bacterial resistance to antibiotics might be different. 
Because of the common complication of furazolidone 
and high cost of clarithromycin, many Iranian physicians 
routinely prefer to use metronidazole, amoxicillin, bismuth, 
and omeprazole for H. pylori eradication [4]. In this 
study, the patients in triple therapy for ten days received 
omeprazole 20 mg twice a day, amoxicillin 1 g twice a 
day, and clarithromycin 500 mg twice a day; however, 
the patients in the sequential therapy group for five days 
received omeprazole 20 mg twice a day and amoxicillin 1 g 
twice a day; in the next five days, they received levofloxacin 
250 mg twice a day, omeprazole 20 mg twice a day, and 
tinidazole 500 mg twice a day. In fact, H. pylori resistance 
to these antibiotics might have been a reason for reduced 
efficacy of the regimens in eradication of the bacterial 
infection in this research. Long-term clarithromycin 
monotherapy for the treatment of respiratory tract 
diseases could indeed lead to the increased resistance 
to this antibiotic. H. pylori resistance to clarithromycin 
might also be the most important factor explaining the 
failure of treatment regimens, particularly triple therapy, 
used for the eradication of infection [33-36]. Moreover, it is 
reported that the optimal efficacy of metronidazole-based 
triple and quadruple drug regimens in western countries 
is about 80-95% [5, 15]. However, due to the high rates of 
resistance to metronidazole in Iran [37,38], the eradication 
rate is usually not optimal [4, 39]. In this study, the use of 
the mentioned treatment regimens may have resulted in 
low rates of H. pylori eradication which is consistent with 
the findings of Zhou and colleagues’ study (in 2014) who 
reported the H. pylori resistance to sequential and triple 
therapy regimens [40].
Studies which have compared sequential and triple 
therapy regimens have reported different results, as some 
of them reported the superiority of sequential treatment 
regimen while other others have reported the superiority 
of triple therapy regimen [32, 41-44]. In a study conducted 
by Khaleghi and colleagues, the patients with chronic 
dyspepsia were classified into two groups each consisting 
of 80 people [45]. One of the groups received omeprazole 
and amoxicillin for the first five days and then omeprazole, 
furazolidone, and clarithromycin for the next nine days; 
the other group received quadruple regimen for 14 days 
consisting of omeprazole, amoxicillin, clarithromycin, and 
bismuth. Of all, 50.9% of the patients in the sequential 
therapy group and 49.1% of the patients in the second 
group were cured, and the difference was not statistically 
significant [45]. In another study, Kaboli and colleagues 
investigated 140 patients with dyspepsia and classified 
them into two groups; the first group received omeprazole, 
amoxicillin, and clarithromycin for 14 days and the second 
group (sequential group) first received omeprazole 
and amoxicillin for five days, and then omeprazole, 
clarithromycin, Tinidazole for the next five days; there was 
no significant difference between the two groups in terms 
of H. Pylori eradication [46]. Zullo and colleagues studied 
36 patients who received rabeprazole 20 mg twice a day, 
levofloxacin 250 mg twice a day, and amoxicillin 1 g twice 
a day. According to the results, H. pylori was successfully 
treated in 30 patients [47]. In fact, comparing with the 
sequential regimen used in this study and the obtained 
results, it can be concluded that the H. pylori strains 
resistant to levofloxacin might have been caused by the 
indiscriminate use of antibiotics in this region.
In the present study, considering people in the age group 
over 40 years, the eradication rate in the triple therapy 
group (69%) was higher than the eradication rate in the 
sequential therapy group (33.3%) (p = 0.045). To justify 
these results, it can be concluded that the use of sequential 
therapy regime, especially for older people, is more difficult 
than that of triple therapy regimen. The more complex 
schedule for taking sequential therapy regimen, especially 
in people over 40 years of age, may increase the risk of 
treatment failure in this study. Nevertheless, Hashemi and 
colleagues (in 2007) reported that patients’ age had no 
significant relationship with the eradication of H. pylori [4].
Higher education level is reported as a factor influencing 
the eradication of H. pylori infection. In this study, the 
highest level of eradication was observed in people with 
an academic degree. These findings are in line with other 
studies in this field that have proven H. pylori infection is 
lower among people with higher education levels [48-50]. 
People with lower education level are indeed at a higher 
risk of infection than those with higher education levels; 
such a negative relationship is also observed between 
parents’ education and infection [51,52].
The results of this study showed that men had a better 
response to treatments than women. It is inconsistent 
with the results of studies by Misattari and Hashemi which 
reported no statistically significant difference between 
men and women in terms of the response to treatments; 
however, in this study in patients in the triple therapy group, 
there was no significant difference between the two sexes 
in terms of response to treatments [4, 32, 53].
Given the low rate of H. Pylori eradication by the sequential 
and triple therapy regimens observed in this study, further 
research must be conducted to study the resistance of 
the bacteria to the studied treatment lines and antibiotics 
in Iran. Considering the results of this study, it is also 
recommended to utilize other treatment regimens to 
achieve higher rates of eradication. It is also suggested 
to use more effective and simple treatment regimens for 
older people and those with lower education levels.
Conclusion
The use of sequential therapy regimen containing 
levofloxacin for the eradication of H. pylori results in 
outcomes which are less than the optimal levels. However, 
further studies in this field are needed to be carried out 
with larger sample size in different places.
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